Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, Technical Operations

Chairman, President and CEO

Chief Accounting Officer

EVP and Chief Medical Officer

EVP, Chief Financial Officer

EVP, Chief Strategy Officer

EVP, General Counsel

EVP, Research & Development

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medi...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	EVP, Technical Operations
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	Chairman, President and CEO
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	Chief Accounting Officer
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	EVP and Chief Medical Officer
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	EVP, Chief Financial Officer
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	-
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	Chairman, President and CEO
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	Chairman, President and CEO
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	EVP, Chief Strategy Officer
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	EVP, General Counsel
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	EVP, Research & Development
2023-10-06	Premium	back to issuer	Premium	Premium	Premium	EVP and Chief Medical Officer

HZNP - Horizon Therapeutics Plc Stock Price, Fair Value and News

Latest Insider Trading transactions for HZNP